ArticleEuropean journal of nuclear medicine and molecular imaging2014
FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity.
Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2015Pooled it
- Quantifying [¹⁸F]fluorodeoxyglucose uptake in the arterial wall: the effects of dual time-point imaging and partial volume effect correction.European journal of nuclear medicine and molecular imaging · 2015Trial
- Hybrid Molecular Imaging Using PET/CT and PET/MRI in Inflammatory Bowel Disease: Current Applications, Challenges, and Future Perspectives.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Comparison of [Molecular imaging and biology · 2026Article
- Role of Total Body PET/CT in Inflammatory Disorders.Seminars in nuclear medicine · 2025Review
- Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite positive positron-emission tomography results.Surgical case reports · 2024Article
- 18F-FDG-PET and other imaging modalities in the diagnosis and management of inflammatory bowel disease.American journal of nuclear medicine and molecular imaging · 2024Review
- The value of FDG-PET/CT imaging in the assessment, monitoring, and management of COVID-19.European physical journal plus · 2023Review
- Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).PET clinics · 2022Article
- The critical role of FDG-PET/CT imaging in assessing systemic manifestations of COVID-19 infection.European journal of nuclear medicine and molecular imaging · 2021Article
- Utility of FDG PET/CT in assessing bowel inflammation.American journal of nuclear medicine and molecular imaging · 2021Article
- Reinventing Molecular Imaging with Total-Body PET, Part II: Clinical Applications.PET clinics · 2020Review
- Toward Molecular Imaging of Intestinal Pathology.Inflammatory bowel diseases · 2020Review
- Assessment of Ileocolonic Inflammation in Crohn's Disease: Which Surrogate Marker Is Better-MaRIA, Clermont, or PET/MR Index? Initial Results of a Feasibility Trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease.American journal of nuclear medicine and molecular imaging · 2019Article
- What can be and what cannot be accomplished with PET to detect and characterize atherosclerotic plaques.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- [European journal of nuclear medicine and molecular imaging · 2018Article
- Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers.Digestive diseases and sciences · 2018Observational
- Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.World journal of radiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to determine the feasibility and potential clinical utility of assessment of Crohn's disease (CD) activity by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT employing a new quantitative approach.
methodsA total of 22 subjects (mean age 37) with CD who had undergone FDG PET/CT followed by ileocolonoscopy within 1 week were included in this analysis. The CD endoscopy index of severity (CDEIS) for various bowel segments was calculated. The CD activity index (CDAI) was evaluated, and fecal calprotectin was measured. On PET, regions with increased FDG uptake in large bowel were segmented with an adaptive contrast-oriented thresholding algorithm, and metabolically active volume (MAV), uncorrected mean standardized uptake value (SUV(mean)), partial volume-corrected SUV(mean) (PVC-SUV(mean)), SUV(max), uncorrected total lesion glycolysis (TLG = MAV × SUV(mean)), and PVC total lesion glycolysis (PVC-TLG = MAV × PVC-SUV(mean)) were measured. Global CD activity score (GCDAS) was calculated as the sum of PVC-TLG over all clinically significant FDG-avid regions in each subject. Correlations between regional PET quantification measures (SUVs, TLGs) and CDEIS were calculated. Correlations between the global PET quantification measure (GCDAS, global SUVs) with CDAI, fecal calprotectin, CDEIS, and CRP level were also calculated.
resultsSUV(max), PVC-SUV(mean), and PVC-TLG significantly correlated with segment CDEIS subscores (r = 0.50, r = 0.69, and r = 0.31, respectively; p < 0.05). GCDAS significantly correlated with CDAI and fecal calprotectin (r = 0.64 and r = 0.51, respectively; p < 0.05).
conclusionBy employing this new quantitative approach, we were able to calculate indices of regional and global CD activity, which correlated well with both clinical and pathological disease activity surrogate markers. This approach may be of clinical importance in measuring both global disease activity and treatment response in patients with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.